Literature DB >> 11793476

A robust method for detecting CHK2/RAD53 mutations in genomic DNA.

Nayanta Sodha1, Richard S Houlston, Richard Williams, Martin A Yuille, John Mangion, Rosalind A Eeles.   

Abstract

While screening for germline CHK2 mutations in cancer cases by heteroduplex CSGE, we observed that additional PCR fragments were generated from the 3' end region of the gene that includes exons 11-14. Direct sequencing of these fragments suggested that homologous loci (possibly pseudogenes) were concomitantly being amplified. Searches of public sequence databases showed that a number of areas of the genome show a high degree of homology to exons 10-14 of the CHK2 gene. The presence of these homologous regions means that standard screening methods for detecting mutations in CHK2, based on PCR of genomic DNA, are prone to error. To circumvent this problem, we have developed a strategy, based on long-range PCR, to screen the functional copy of CHK2. Using this approach it is possible to carry out a comprehensive mutational analysis of CHK2 from genomic DNA. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11793476     DOI: 10.1002/humu.10031

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  13 in total

1.  Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratoma.

Authors:  Yuesheng Jin; Fredrik Mertens; Carl-Magnus Kullendorff; Ioannis Panagopoulos
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

Review 2.  ATM and genome maintenance: defining its role in breast cancer susceptibility.

Authors:  Kum Kum Khanna; Georgia Chenevix-Trench
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

3.  Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

Authors:  Mieke Schutte; Sheila Seal; Rita Barfoot; Hanne Meijers-Heijboer; Marijke Wasielewski; D Gareth Evans; Diana Eccles; Carel Meijers; Frans Lohman; Jan Klijn; Ans van den Ouweland; P Andrew Futreal; Katherine L Nathanson; Barbara L Weber; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Am J Hum Genet       Date:  2003-02-27       Impact factor: 11.025

4.  A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.

Authors:  N Wang; H Ding; C Liu; X Li; L Wei; J Yu; M Liu; M Ying; W Gao; H Jiang; Y Wang
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

5.  Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer.

Authors:  Marc D Tischkowitz; Ahmet Yilmaz; Long Q Chen; Danielle M Karyadi; David Novak; Tomas Kirchhoff; Nancy Hamel; Sean V Tavtigian; Suzanne Kolb; Tarek A Bismar; Raquel Aloyz; Peter S Nelson; Lee Hood; Steven A Narod; Kirsten A White; Elaine A Ostrander; William B Isaacs; Kenneth Offit; Kathleen A Cooney; Janet L Stanford; William D Foulkes
Journal:  Cancer Lett       Date:  2008-06-20       Impact factor: 8.679

6.  The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.

Authors:  Hanne Meijers-Heijboer; Juul Wijnen; Hans Vasen; Marijke Wasielewski; Anja Wagner; Antoinette Hollestelle; Fons Elstrodt; Renate van den Bos; Anja de Snoo; Grace Tjon A Fat; Cecile Brekelmans; Shantie Jagmohan; Patrick Franken; Paul Verkuijlen; Ans van den Ouweland; Pamela Chapman; Carli Tops; Gabriela Möslein; John Burn; Henry Lynch; Jan Klijn; Riccardo Fodde; Mieke Schutte
Journal:  Am J Hum Genet       Date:  2003-04-10       Impact factor: 11.025

7.  Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.

Authors:  Muhammad U Rashid; Noor Muhammad; Saima Faisal; Asim Amin; Ute Hamann
Journal:  BMC Cancer       Date:  2013-06-27       Impact factor: 4.430

8.  Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.

Authors:  Florence Le Calvez-Kelm; Fabienne Lesueur; Francesca Damiola; Maxime Vallée; Catherine Voegele; Davit Babikyan; Geoffroy Durand; Nathalie Forey; Sandrine McKay-Chopin; Nivonirina Robinot; Tù Nguyen-Dumont; Alun Thomas; Graham B Byrnes; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Sean V Tavtigian
Journal:  Breast Cancer Res       Date:  2011-01-18       Impact factor: 6.466

9.  CHEK2 contribution to hereditary breast cancer in non-BRCA families.

Authors:  Alexis Desrichard; Yannick Bidet; Nancy Uhrhammer; Yves-Jean Bignon
Journal:  Breast Cancer Res       Date:  2011-11-24       Impact factor: 6.466

10.  The CHEK2(*)1100delC mutation has no major contribution in oesophageal carcinogenesis.

Authors:  L B Koppert; M Schutte; M Abbou; H W Tilanus; W N M Dinjens
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.